Inovio Pharmaceuticals Inc INO

NAS: INO | ISIN: US45773H2013 8/12/2023

0,380 USD (+0,53%)

(+0,53%) 8/12/2023

Grafiek Inovio Pharmaceuticals Inc

Grafiek Inovio Pharmaceuticals Inc

1 dag1d 0,53%
1 week1w -6,17%
1 maand1m 8,57%
3 maanden3m -17,03%
6 maanden6m -23,31%
1 jaar1j -79,35%
5 jaar5j -92,68%

Inovio Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

9 november 2023 · INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights · Persbericht

1 november 2023 · INOVIO Reports Inducement Grants Under Inducement Plan · Persbericht

26 oktober 2023 · INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 · Persbericht

10 oktober 2023 · INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program · Persbericht

28 september 2023 · Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million · Persbericht

7 september 2023 · INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

29 augustus 2023 · INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

9 augustus 2023 · INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update · Persbericht

4 augustus 2023 · INOVIO Reports Inducement Grants Under Inducement Plan · Persbericht

26 juli 2023 · INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023 · Persbericht

Profiel Inovio Pharmaceuticals Inc

Gezondheidstechnologie

Medische Specialiteiten

Productie van wapens en munitie

Website: www.inovio.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Jong Kim

Werknemers: 309

Aandelen Inovio Pharmaceuticals Inc

Beurswaarde: 103,73 miljoen USD

Effecten: 272,99 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,79

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe